Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $8.09M |
| Net Income (Most Recent Fiscal Year) | $-124.70M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.01 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -68.15% |
| Return on Assets (Trailing 12 Months) | -55.33% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.89 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.89 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.43 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.59 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.95 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.99 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 77.51M |
| Free Float | 76.04M |
| Market Capitalization | $297.66M |
| Average Volume (Last 20 Days) | 1.73M |
| Beta (Past 60 Months) | 2.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 81.46% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |